Serum levels of soluble surface markers AXL and C-MET, described for cancer stem cells in rectal cancer, possibly can correlate with clinicopathological characteristics and patient outcome data with respect to neoadjuvant chemoradiotherapy. The gene discussed is MET; the disease is rectal cancer.